Related Experiment Video
Updated: May 21, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
A pediatric non-protein losing Menetrier's disease successfully treated with octreotide long acting release
Giovanni Di Nardo1, Salvatore Oliva, Marina Aloi
1Department of Pediatrics, Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, 00161 Rome, Italy.
Abstract:
Pediatric Menetrier's disease (MD) is an uncommon, acute, self-limited hypertrophic gastropathy characterized by enlarged gastric folds associated with epithelial hyperplasia and usually accompanied by protein losing gastropathy. Gastric cytomegalovirus infection is found in one third of MD children and its treatment is often associated with remission. Diagnosis often requires full-thickness biopsy due to inability to detect typical histological findings with conventional endoscopic biopsy. We report an uncommon case of non self-limited pediatric MD needing endoscopic mucosal resection for diagnosis which was then successfully treated with octreotide long-acting release (LAR). To the best of our knowledge, this is the first pediatric MD case successfully treated with octreotide LAR. Our experience suggests octreotide LAR as treatment for refractory MD before gastrectomy.
Insights
Pediatric Menetrier
Area of Science:
- Pediatric Gastroenterology
- Gastrointestinal Pathology
Background:
- Menetrier's disease (MD) is a rare hypertrophic gastropathy in children, often self-limiting.
- It involves enlarged gastric folds, epithelial hyperplasia, and protein-losing gastropathy.
Observation:
- A case of non self-limited pediatric MD required endoscopic mucosal resection for diagnosis.
- This patient had previously undergone conventional endoscopic biopsy without definitive findings.
Findings:
- The pediatric MD case was successfully treated with octreotide long-acting release (LAR).
- This represents the first reported pediatric MD case managed with octreotide LAR.
Implications:
- Octreotide LAR may be a viable treatment for refractory pediatric MD, potentially avoiding gastrectomy.
- This suggests a new therapeutic avenue for challenging MD cases.